Research Topics
| S Dupuis-GirodSummaryAffiliation: Hospices Civils de Lyon Country: France Publications
|
Detail Information
Publications
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac outputSophie Dupuis-Girod
Hospices Civils de Lyon, Hopital Louis Pradel, Genetic Department and National Reference Center for Rendu Osler Disease, Bron, France
JAMA 307:948-55. 2012..Anti-vascular endothelial growth factor treatments such as bevacizumab may be an effective treatment...
Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated associationSophie Dupuis-Girod
Service de Génétique et Centre de Référence sur la Maladie de Rendu Osler, hôpital de l Hôtel dieu, Lyon, France
Clin Infect Dis 44:841-5. 2007..Cerebral infections accounted for 33% of all infections, were mainly due to multiple and anaerobic bacteria, and were associated with the presence of pulmonary arteriovenous malformations and a short duration of epistaxis...
Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center studySophie Dupuis-Girod
Service de Génétique et Centre de Référence pour la Maladie de Rendu Osler, Lyon, France
Liver Transpl 16:340-7. 2010..In conclusion, OLT is an important therapeutic option for patients with HHT who have severe hepatic involvement. In the reported cohort, the mortality after OLT for this indication was low...
Hereditary hemorrhagic telangiectasia: from molecular biology to patient careS Dupuis-Girod
Service de Génétique et Centre de Référence National Maladies Rares, maladie de Rendu Osler, Hospices Civils de Lyon, hôpital de l Hôtel dieu, Lyon, France
J Thromb Haemost 8:1447-56. 2010....
